Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer

British Journal of Cancer

Volumn 98, Issue 10, 2008, Pages 1690-1695

  Nomoto, S ^a   Kinoshita, T ^a   Mori, T ^a   Kato, K ^a   Sugimoto, H ^a   Kanazumi, N ^a   Takeda, S ^a   Nakao, A ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypermethylation; Loss of heterozygosity; Pancreatic cancer; RUNX3

Indexed keywords

BISULFITE; DNA;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUNX3 GENE; SIGNAL TRANSDUCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 1; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 43649094855     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604333     Document Type: Article

References (20)

1. Bisgaard HC, Thorgeirsson SS (1991) Evidence for a common cell of origin for primitive epithelial cells isolated from rat liver and pancreas. J Cell Physiol 147: 333-343
2. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93: 1159-1170
3. Ito Y, Miyazono K (2003) RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 13: 43-47
4. Japan Pancreatic Society (2003) Classification of Pancreatic Carcinoma 2nd English edn, Tokyo: Kanehara
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
6. Kern SE, Hruban RH, Hidalgo M, Yeo CJ (2002) An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 1: 607-613
7. Li J, Kleeff J, Guweidhi A, Esposito I, Berberat PO, Giese T, Büchler MW, Friess H (2004) RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 57: 294-299
8. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124
9. Logsdon CD, Keyes L, Beauchamp RD (1992) Transforming growth factor-beta (TGF-beta 1) inhibits pancreatic acinar cell growth. Am J Physiol 262: 364-368
10. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, Ohki M, Inazawa J, Hirohashi S (2007) Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 98: 392-400
11. Massagu J, Blain SW, Lo RS (2000) TGF β signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309
12. Miyazono K, Suzuki H, Imamura T (2003) Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94: 230-234
13. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, Carter R, Goggins MG, Hruban RH, Maitra A (2005) Genome - wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 161: 36-50
14. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Büchler MW (2001) Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 21: 27-44
15. Pour PM, Pandey KK, Batra SK (2003) What is the origin of pancreatic adenocarcinoma? Mol Cancer 2: 13
16. Sakurada K, Furukawa T, Kato Y, Kayama T, Huang S, Horii A (2001) RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and colorectum. Genes Chromosomes Cancer 30: 207-211
17. Schwab M, Praml C, Amler LC (1996) Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 16: 211-229
18. Sphyris N, Morris RG, Harrison DJ (2004) Induction of p21 and nuclear accumulation of TAp73alpha and c-abl during apoptosis of cisplatin-treated primary pancreatic acinar cells. Int J Oncol 25: 1661-1670
19. Tokumaru Y, Nomoto S, Jerónimo C, Henrique R, Harden S, Trink B, Sidransky D (2003) Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 22: 6954-6958
20. Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura C, Ito K, Ito Y, Chiba T (2004) Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 23: 2401-2407